The implants were made on a temporary production line set up in Bergen in August. Two implants passed functional testing in Bergen and then completed in-vitro and end-of-line testing at Lifecare Chemistry in Bristol, UK, where they produced stable, measurable signals. They are expected to go into Lifecare’s ongoing veterinary development program once final pre-implantation testing is complete.

Lifecare notes that controlled manufacturing is not yet in place. That requires showing repeatability, process control, traceability and quality documentation across a larger number of implants. The production line has since moved to new facilities at Ocean TuniCell’s premises in Bergen, where production is expected to start shortly. The company still aims to establish controlled manufacturing during autumn 2026.

“For the first time, functional implants have been manufactured by Lifecare’s own team,” said CEO Joacim Holter.